Myriad Says myPath Melanoma Test Highly Effective in Verification Study

Myriad Genetics, Inc. (Nasdaq: MYGN ) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable information provided by myPath Melanoma will empower healthcare providers with objective data and improve the diagnosis of patients with melanoma. Myriad presented these data at